Originally posted by genericforms
View Post
Seqanswers Leaderboard Ad
Collapse
Announcement
Collapse
No announcement yet.
X
-
Originally posted by ulz_peter View PostI could write an E-mail to GenomeBiology, although I don't know anyone there, but it won't hurt, right?. Genericforms: you could send me the E-mail you've sent via PM, just to see what you mentioned?Marco
Comment
-
Everyone,
Here is the response I got:
"In principle, we are interested in the manuscript you describe and we
think it might be suitable as a Correspondence article, although we
would need to see the full manuscript before making a decision. For this
manuscript to be considered by Genome Medicine, it would need to be
clear that it contains information that is not included in the recently
published Nucleic Acids Research issue and that it is applicable and
relevant to medical/clinical researchers as well as basic scientists.
Correspondence articles are open access, peer-reviewed articles that
include brief reports of particular interest to the community
(http://genomemedicine.com/authors/in...correspondence). To
submit the article, please go to http://genomemedicine.com/manuscript."
So we have two things to address:
1. Is the paper different than the NAR paper?
2. We need to clarify (if we publish in Genome Medicine) how this resources helps basic scientists as well as those that are interested in medical/clinical research.
I think these are both easy tasks. Question is: How do you want to proceed? We should finalize as soon as possible.
Comment
-
Originally posted by genericforms View PostEveryone,
Here is the response I got:
"In principle, we are interested in the manuscript you describe and we
think it might be suitable as a Correspondence article, although we
would need to see the full manuscript before making a decision. For this
manuscript to be considered by Genome Medicine, it would need to be
clear that it contains information that is not included in the recently
published Nucleic Acids Research issue and that it is applicable and
relevant to medical/clinical researchers as well as basic scientists.
Correspondence articles are open access, peer-reviewed articles that
include brief reports of particular interest to the community
(http://genomemedicine.com/authors/in...correspondence). To
submit the article, please go to http://genomemedicine.com/manuscript."
So we have two things to address:
1. Is the paper different than the NAR paper?
2. We need to clarify (if we publish in Genome Medicine) how this resources helps basic scientists as well as those that are interested in medical/clinical research.
I think these are both easy tasks.
Briefly, in the wiki we described why SEQanswers is a credible community that lead to the wiki. In contrast, the correspondence/letter we are writing here want to say that SEQanswers is more than a scientific forum alone. SEQanswers, being a technical NGS focusd forum....served bioinformaticians.....
IS an example and advocate of OPEN SCIENCE...We want to focus on the IMPLICATION of SEQanswers rather than the technical stuff of SEQanswersMarco
Comment
-
Originally posted by genericforms View PostEveryone,
Here is the response I got:
"In principle, we are interested in the manuscript you describe and we
think it might be suitable as a Correspondence article, although we
would need to see the full manuscript before making a decision. For this
manuscript to be considered by Genome Medicine, it would need to be
clear that it contains information that is not included in the recently
published Nucleic Acids Research issue and that it is applicable and
relevant to medical/clinical researchers as well as basic scientists.
Correspondence articles are open access, peer-reviewed articles that
include brief reports of particular interest to the community
(http://genomemedicine.com/authors/in...correspondence). To
submit the article, please go to http://genomemedicine.com/manuscript."
So we have two things to address:
1. Is the paper different than the NAR paper?
2. We need to clarify (if we publish in Genome Medicine) how this resources helps basic scientists as well as those that are interested in medical/clinical research.
I think these are both easy tasks. Question is: How do you want to proceed? We should finalize as soon as possible.Marco
Comment
-
Originally posted by marcowanger View PostFor 1>, I am not sure how should we argue. But I would say the NAR paper is MORE about the wiki (well, the title is The SEQanswers wiki). That was why I stressed not to copy the writings in the NAR paper. Before the actual publication, I have put the draft of the paragraph about SEQanswers into the wiki.
Briefly, in the wiki we described why SEQanswers is a credible community that lead to the wiki. In contrast, the correspondence/letter we are writing here want to say that SEQanswers is more than a scientific forum alone. SEQanswers, being a technical NGS focusd forum....served bioinformaticians.....
IS an example and advocate of OPEN SCIENCE...We want to focus on the IMPLICATION of SEQanswers rather than the technical stuff of SEQanswers
Comment
-
Regarding how to proceed
[My opinion]
Consider
(1) reader's base
(2) impact to the field (impact factor?!?)
(3) Open Access journal? Is kind of weird to publish a OPEN SCIENCE forum in a closed source journal
(4) difficulty to publish in that journal.
[/My opinion]
[action]
send inquiry email to all editors. See how they say. And make the rational choices given all the choices.
[/action]
Originally posted by genericforms View PostEveryone,
Here is the response I got:
"In principle, we are interested in the manuscript you describe and we
think it might be suitable as a Correspondence article, although we
would need to see the full manuscript before making a decision. For this
manuscript to be considered by Genome Medicine, it would need to be
clear that it contains information that is not included in the recently
published Nucleic Acids Research issue and that it is applicable and
relevant to medical/clinical researchers as well as basic scientists.
Correspondence articles are open access, peer-reviewed articles that
include brief reports of particular interest to the community
(http://genomemedicine.com/authors/in...correspondence). To
submit the article, please go to http://genomemedicine.com/manuscript."
So we have two things to address:
1. Is the paper different than the NAR paper?
2. We need to clarify (if we publish in Genome Medicine) how this resources helps basic scientists as well as those that are interested in medical/clinical research.
I think these are both easy tasks. Question is: How do you want to proceed? We should finalize as soon as possible.Marco
Comment
-
Sounds good. Sometimes editors are not as quick to reply as the one I contacted. Go ahead and email other editors but we should set a final date at which we do not wait any further for replies and make a choice assuming there is one.
In the meantime I think we should aim to wrap the paper up next week if possible.
Comment
-
Originally posted by marcowanger View PostI will help contact the rest.
PLoS Biology seems to be a good choice because they specifically has a article type called "Community Page" !
But they need abstract, cover letter , etc.. for pre-submission inquiry
I still vote for Genome Medicine.
Comment
-
Originally posted by genericforms View PostLet's just finish the paper so we have all these things and a final author list and paper title. Then we can delay submission for a couple days while we inquire about submission. But really if they need all that, we might as well just submit. Turn around time at PLOS is quick.
I still vote for Genome Medicine.Marco
Comment
-
Great stuff going on here...
Another question: How do we cover the publication fees (as far as I've seen it, it would be 2900$ for the PLoS journals and $2490 for the Genome* journals)?
And how do we select the title?
My vote goes for Joann's title:
SEQanswers, Reading Biological Sequences as a Community since 2007.
Comment
-
Originally posted by ulz_peter View PostGreat stuff going on here...
Another question: How do we cover the publication fees (as far as I've seen it, it would be 2900$ for the PLoS journals and $2490 for the Genome* journals)?
And how do we select the title?
My vote goes for Joann's title:
SEQanswers, Reading Biological Sequences as a Community since 2007.
I would in favor in replacing "reading" with "Collective Intelligence in decoding", so.
"SEQanswers, Collective Intelligence in Decoding Biological Sequences since 2007"Marco
Comment
Latest Articles
Collapse
-
by seqadmin
While isolating and preparing single cells for sequencing was historically the bottleneck, recent technological advancements have shifted the challenge to data analysis. This highlights the rapidly evolving nature of single-cell sequencing. The inherent complexity of single-cell analysis has intensified with the surge in data volume and the incorporation of diverse and more complex datasets. This article explores the challenges in analysis, examines common pitfalls, offers...-
Channel: Articles
06-06-2024, 07:15 AM -
-
by seqadmin
Technological advances have led to drastic improvements in the field of precision medicine, enabling more personalized approaches to treatment. This article explores four leading groups that are overcoming many of the challenges of genomic profiling and precision medicine through their innovative platforms and technologies.
Somatic Genomics
“We have such a tremendous amount of genetic diversity that exists within each of us, and not just between us as individuals,”...-
Channel: Articles
05-24-2024, 01:16 PM -
ad_right_rmr
Collapse
News
Collapse
Topics | Statistics | Last Post | ||
---|---|---|---|---|
Started by seqadmin, Today, 02:20 PM
|
0 responses
9 views
0 likes
|
Last Post
by seqadmin
Today, 02:20 PM
|
||
Started by seqadmin, 06-07-2024, 06:58 AM
|
0 responses
181 views
0 likes
|
Last Post
by seqadmin
06-07-2024, 06:58 AM
|
||
Started by seqadmin, 06-06-2024, 08:18 AM
|
0 responses
228 views
0 likes
|
Last Post
by seqadmin
06-06-2024, 08:18 AM
|
||
Started by seqadmin, 06-06-2024, 08:04 AM
|
0 responses
184 views
0 likes
|
Last Post
by seqadmin
06-06-2024, 08:04 AM
|
Comment